ReviewCells2021
Artificial Intelligence & Tissue Biomarkers: Advantages, Risks and Perspectives for Pathology.
Review in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 58 citations in OpenAlex.
- Inflammatory Biomarkers Following Orthopedic Surgery: Current Evidence, Clinical Applications, and Future Perspectives-A Narrative Review.Journal of clinical medicine · 2026Review
- Decoding Temporomandibular Disorders: Identifying Stage-Specific and Functional Patterns in the Articular Disc.Stem cell reviews and reports · 2026Review
- Integrating AI and RNA biomarkers in cancer: advances in diagnostics and targeted therapies.Cell communication and signaling : CCS · 2025Review
- Unconventional Immunotherapies in Cancer: Opportunities and Challenges.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Predicting ROS1 and ALK fusions in NSCLC from H&E slides with a two-step vision transformer approach.NPJ precision oncology · 2025Article
- Article
- Multimodal AI in Biomedicine: Pioneering the Future of Biomaterials, Diagnostics, and Personalized Healthcare.Nanomaterials (Basel, Switzerland) · 2025Review
- Perspectives on Reducing Barriers to the Adoption of Digital and Computational Pathology Technology by Clinical Labs.Diagnostics (Basel, Switzerland) · 2025Article
- Patient Consent and The Right to Notice and Explanation of AI Systems Used in Health Care.The American journal of bioethics : AJOB · 2025Article
- Enhancing glioma immunohistochemical image classification through color deconvolution-aware prior guidance.PloS one · 2025Article
- Computational pathology: A survey review and the way forward.Journal of pathology informatics · 2024Review
- Article
- A glimpse into the future: Integrating artificial intelligence for precision HER2-positive breast cancer management.iMetaOmics · 2024Review
- Article
- Present and Future of Artificial Intelligence in Pathology.Balkan medical journal · 2024Article
- Unveiling the Influence of AI Predictive Analytics on Patient Outcomes: A Comprehensive Narrative Review.Cureus · 2024Review
- Nonsurgical approaches to the diagnosis and evaluation of endometriosis.Fertility and sterility · 2024Review
- Artificial intelligence for chimeric antigen receptor-based therapies: a comprehensive review of current applications and future perspectives.Therapeutic advances in vaccines and immunotherapy · 2024Review
- Artificial intelligence and bioinformatics: a journey from traditional techniques to smart approaches.Gastroenterology and hepatology from bed to bench · 2024Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
Abstract
Tissue Biomarkers are information written in the tissue and used in Pathology to recognize specific subsets of patients with diagnostic, prognostic or predictive purposes, thus representing the key elements of Personalized Medicine. The advent of Artificial Intelligence (AI) promises to further reinforce the role of Pathology in the scenario of Personalized Medicine: AI-based devices are expected to standardize the evaluation of tissue biomarkers and also to discover novel information, which would otherwise be ignored by human review, and use them to make specific predictions. In this review we will present how AI has been used to support Tissue Biomarkers evaluation in the specific field of Pathology, give an insight to the intriguing field of AI-based biomarkers and discuss possible advantages, risk and perspectives for Pathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.